Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Trial Profile

Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Palbociclib (Primary) ; Fulvestrant; Letrozole
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms PALINA
  • Most Recent Events

    • 12 Oct 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
    • 12 Oct 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 11 Jul 2016 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top